



DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ming-Hui WEI, et al.

Art Unit: 1632

Serial No.: 10/663,794

Examiner: TBA

Filed: September 17, 2003

Atty. Docket: CL001164CIP-DIV II

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN KINASE
PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

By:


Justin D. Karjala, Reg No. 43,704

Date: December 12, 2005

Celera Genomics
45 West Gude Drive, C1-1#316
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Approved for use through 10/31/2002. OMB 0651-0031

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/663,794
Filing Date	September 17, 2003
First Named Inventor	Ming-Hui WEI, et al.
Art Unit	1632
Examiner Name	TBA
Attorney Docket Number	CL001164CIP-DIV II

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
		WO 01/38503 A	03-31-2001	SUGEN, INC; PLOWMA..	
		WO 01/96547 A	12-20-2001	INCYTE GENOMICS INC..	
		WO 02/33099 A	04-25-2002	INCYTE GENOMICS, INC...	
		WO 02/34896 A	05-02-2002	MILLENNIUM PHARMA...	
		WO 02/26826 A	04-04-2002	CURAGEN CORPORATI...	
		WO 03/004629 A	01-16-2003	BAYER AKTIENGESELL...	
		WO 02/059325 A	08-01-2002	LEXICON GENETICS IN...	
		WO 03/004523 A	01-16-2003	BAYER AKTIENGESELL...	
		WO 03/087332 A	10-23-2003	BRISTOL-MYERS SQUIB...	
		WO03/029424 A	04-10-2003	CURAGEN CORPORATI...	

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST: 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/663,794	
			Filing Date	September 17, 2003	
			First Named Inventor	Ming-Hui WEI, et al.	
			Art Unit	1632	
			Examiner Name	TBA	
Sheet	2	of	3	Attorney Docket Number	CL001164CIP-DIV II

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO2004/006838 A	01-22-2004	SUGEN, INC.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/663,794
		Filing Date	September 17, 2003
		First Named Inventor	Ming-Hui WEI, et al.
		Group Art Unit	1632
		Examiner Name	TBA
		Attorney Docket Number	CL001164CIP-DIV II
Sheet	3	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XIII. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO"; DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 6, 1999, pages 63-70, XP001000446; ISSN: 1340-2838	
		DATABASE EMBL Homo sapiens, mRNA, similar to citron 17 July 2001 (2001-07-17), DTRAUSBERG: "BC008127"; XP002337009; Database accession no. BC008127; 325 nucleotides, 100% identical to SEQ ID NO:1	
		DATABASE EMBL homologous to serine/threonine protein kinases; 3 March 1997 (1997-03-03), COX: "HS6ET4P4, Homo sapiens PAC trapped exon"; XP002337010; Database accession no. Y11242 143 nucleotides, 100% identical to SEQ ID NO:1	
		DATABASE EMBL 23 March 2000 (2000-03-23); MUZNY ET AL.: "Homo sapiens chromosome 12 clone RP11-184J5"; XP002337011; Database accession no. AC026363 comprises 178 nt identical to SEQ ID NO: 1	
		HANKS S K ET AL: "THE EUKARYOTIC PROTEIN KINASE SUPERFAMILY: KINASE (CATLYTIC) DOMAIN STRUCTURE AND CLASSIFICATION" FASEB JOURNALS, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 9, May 1995 (1995-05-09), pages 576-596, XP001078836; ISSN: 0892-6638	
		HANKS S K ET AL: "THE PROTEIN KINASE FAMILY: CONSERVED FEATURES AND DEDUCED PHYLOGENY OF THE CATALYTIC DOMAINS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 241 no. 4861, 1 July 1988 (1988-07-01), pages 42-52, XP000613735; ISSN: 0036-8075	
		HANKS S K ET AL: "PROTEIN KINASE CATALYTIC DOMAIN SEQUENCE DATABASE: IDENTIFICATION OF CONSERVED FEATURES OF PRIMARY STRUCTURE AND CLASSIFICATION OF FAMILY MEMBERS"; MELK-SYSTEM BOU-MATIC, OLDENBURG, DE, vol. 200, 1991, pages 38-62, XP000563379	
		HANKS S K ET AL: "USE OF DEGENERATE OLIGONUCLEOTIDE PROBES TO IDENTIFY CLONES THAT ENCODE PROTEIN KINASES"; METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 200, 1991, pages 525-532, XP001096015; ISSN: 0076-6879	
		ZHAO ZHOU-SHEN ET AL: "PAK and other Rho-associated kinases—effectors with surprisingly diverse mechanisms of regulation." THE BIOCHEMICAL JOURNAL. 1 MAR 2005, vol. 386, no. pt 2, 1 March 2005 (2005-03-01), pages 1-50, XP002336982; ISSN: 1470-8728	
Copy of Supplementary Partial European Search Report dated September 12, 2005			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.